the AUROC of vascular diverging angle for discriminating advanced liver fibrosis from mild to moderate liver fibrosis was 0.873 with sensitivity of 94.1% and specificity of 75.0%. Conclusions: The present results indicated that Superb Micro-vascular Imaging potentially predicts hepatic fibrosis by detecting fine vessels present in the vicinity of liver surface, even though further investigation is needed in a large number of patients. Disclosures: Takeshi Sato – Employment: Toshiba Medical Systems Corporation The following people have nothing to disclose: Nobuko Koyama, Jiro Hata, Noriaki Manabe, Hiroshi Imamura, Ken Haruma, Keisuke Hino Background: Liver biopsy is the gold standard used to diagnose hepatic fibrosis/steatosis. Transient elastography which is used in some centers is a non-invasive test selleck chemicals preferred by patients. We investigated the use of a novel technique called shear wave elastography (SWE). Aims:To determine the optimal location for obtaining SWE measurements, compare it with liver biopsy and to investigate the accuracy of grayscale sonography hepatorenal index (HRI) in screening for hepatic steatosis. Methods:100 consecutive patients undergoing percutaneous liver biopsy between Feb 2014 and May 2014 were recruited from the outpatient clinics of Ochsner Medical Center. SWE measurements were obtained in hepatic segments V/VI and VII/
VIII. HRI beta-catenin inhibitor was calculated at the midportion of the right kidney. A single liver pathologist determined liver fibrosis (METAVIR) and steatosis. Analysis of Variance (ANOVA) was employed to analyze the degree of fibrosis and SWE measurements and Student’s t-test was used to analyze HRI and degree of steatosis. Results: Patient characteristics: We investigated 57 males and 43 females- (40 OLT recipients). 54 patients had HCV infection, 14 had hepatomegaly alone and 32 had a variety of autoimmune liver diseases. SWE measurements: There was no correlation found between SWE measurements and age, gender, AST/ALT, bilirubin and the presence of steatosis. There was however, a statistically significant difference in the mean SWE seen in patients with a BMI<40 vs BMI>40 (p<0.0001).
OLT patients had similar SWE values to non-OLT patients. There was no statistically significant SSR128129E inter-observer variation (3 technologists). SWE measurements and fibrosis: Segment VII/VIII SWE was able to distinguish normal liver (p< 0.01) and stage 1 fibrosis (0.008) from stage 4 fibrosis. Similar results were seen with segment V/VI SWE. When SWE measurements for both areas were combined, there was a significant difference between stage 1 vs stage 3 (p<0.011), stage 1 vs stage 4 (p< 0.005) and stage 0 vs stage 4 (p< 0.033). HRI measurements: HRI measurements for patients with <5% steatosis vs those with >5% steatosis were different (P<0.0002). Summary: a) SWE can distinguish normal liver/mild fibrosis from cirrhosis in both non-OLT and OLT patents. b) BMI>40 may affect SWE measurements.